• Cite Icon18
  • https://doi.org/10.2165/00019053-199712030-00011Copy DOI Icon

Dornase Alfa

Show More
  • Abstract
  • Literature Map
  • References
  • Citations
  • Similar Papers
Abstract

Cystic fibrosis (CF) is a fatal hereditary disease; patients with CF have an average lifespan of 30 years. By cleaving neutrophil-derived DNA, dornase alfa (recombinant human deoxyribonuclease I) decreases the adhesiveness and visco-elasticity of sputum in the infected lungs of patients with CF. As a result, respiratory function is improved in patients with all degrees of disease severity, and the relative risk of pulmonary exacerbations is reduced in patients with mild to moderate disease. Resource utilisation (days spent in hospital or receiving parenteral antibiotics) in patients with mild to moderate disease is also reduced by dornase alfa, as evidenced by a placebo-controlled trial in > 900 patients. Cost savings generated by these reductions in resource use during 24 weeks of dornase alfa therapy offset about 17 to 37.5% of the acquisition cost of the drug, depending on local cost data for various countries. Reductions in resource utilisation with dornase alfa have not been observed in patients with severe disease. Available cost-effectiveness and cost-utility analyses are not fully published. One analysis estimated that the incremental cost of avoiding one hospitalisation was about $Can 15,000 relative to standard therapy after 1 year of treatment. Informal analysis in the UK suggests a cost per quality-adjusted life-year of 25,000 Pounds for dornase alfa. Some quality-of-life (QOL) domains (mainly cough frequency and chest congestion) have shown modest improvement in patients treated with dornase alfa, mainly those with mild CF. Persuasive evidence of QOL benefit is lacking in those with more severe disease. Identifying patients most likely to benefit from dornase alfa therapy is essential to maximise clinical and cost benefits. The lack of a demonstrated reduction in resource utilisation in patients with severe CF makes its use more difficult to justify economically in this group than in those with less severe disease. However, in the absence of other treatments for this group, economic considerations must be weighed against clinical benefits. In conclusion, the acquisition cost of dornase alfa is partially offset by savings gained by reducing resource utilisation in patients with mild to moderate CF, and the drug appears to improve quality of life in some patients, mostly those with less severe disease. However, in the absence of guidance from definitive cost-effectiveness analyses, individual healthcare providers must make their own decisions about how best to provide dornase alfa to patients with CF in a rational and cost-justifiable manner.

Similar Papers
  • Front Matter
  • Citations3

Dornase Alfa Therapy in Cystic Fibrosis: Who Should Get It?

  • Oct 01, 1996
  • Chest
  • Jamshed F Kanga
  • Abstract

PND67 A Mixed-Effects Piecewise Linear Model of the Rate of Lung Function Decline Before and After the Clinical Use of Dornase Alfa in an Observational Study of Cystic Fibrosis

  • Oct 27, 2011
  • Value in Health
  • D.J Pasta +2
  • Research Article
  • Citations168

Dornase alfa for cystic fibrosis.

  • Apr 04, 2016
  • The Cochrane database of systematic reviews
  • Connie Yang +3
  • Research Article

Possibilities of using recombinant human deoxyribonuclease I in otorhinolaryngology

  • May 15, 2023
  • Russian Bulletin of Otorhinolaryngology
  • K.V Eremeeva +4
  • Research Article
  • Citations324

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

  • Dec 01, 2001
  • The Journal of Pediatrics
  • Joanne M Quan +7
  • Research Article
  • Citations26

Estimating effectiveness in an observational study: A case study of dornase alfa in cystic fibrosis

  • Jun 01, 1999
  • The Journal of Pediatrics
  • Charles A Johnson +4
  • Research Article
  • Citations22

Thymosin β4 Sequesters Actin in Cystic Fibrosis Sputum and Decreases Sputum Cohesivity in Vitro

  • Nov 01, 2006
  • Chest
  • Bruce K Rubin +2
  • Research Article
  • Citations1

Clinical and functional control of mucolytic therapy in children with cystic fibrosis

  • Apr 06, 2022
  • Meditsinskiy sovet = Medical Council
  • O I Simonova +2
  • Research Article
  • Citations47

Sputum processing for evaluation of inflammatory mediators.

  • Jul 24, 2001
  • Pediatric Pulmonology
  • Jung‐Soo Kim +3
  • Research Article
  • Citations25

Dornase alfa is well tolerated: Data from the Epidemiologic Registry of Cystic Fibrosis

  • Aug 28, 2007
  • Pediatric Pulmonology
  • S.G Mckenzie +3
  • Research Article
  • Citations116

Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.

  • Jul 12, 2013
  • The Cochrane database of systematic reviews
  • Julian Tam +4
  • Research Article
  • Citations10

Bronchoscopic instillation of DNase to manage refractory lobar atelectasis in a lung cancer patient.

  • Aug 01, 2019
  • Annals of translational medicine
  • Hussein Assallum +3
  • Research Article

Surgical and medical management of chronic rhinosinusitis in pediatric cystic fibrosis patients: Impact on olfactory symptoms

  • Feb 28, 2024
  • International journal of pediatric otorhinolaryngology
  • Holly D Shan +6
  • Research Article
  • Citations8

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention.

  • Jul 03, 2017
  • Pediatric Pulmonology
  • Michael W Konstan +5
  • Book Chapter
  • Citations4

The Changing Face of Cystic Fibrosis

  • Jan 01, 2020
  • Jonathan D Cogen +1
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.